GB0008269D0 - Combination chemotherapy - Google Patents

Combination chemotherapy

Info

Publication number
GB0008269D0
GB0008269D0 GBGB0008269.3A GB0008269A GB0008269D0 GB 0008269 D0 GB0008269 D0 GB 0008269D0 GB 0008269 A GB0008269 A GB 0008269A GB 0008269 D0 GB0008269 D0 GB 0008269D0
Authority
GB
United Kingdom
Prior art keywords
agent
combination
angiogenesis
warm
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0008269.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0008269.3A priority Critical patent/GB0008269D0/en
Publication of GB0008269D0 publication Critical patent/GB0008269D0/en
Priority to DE60126923T priority patent/DE60126923T2/de
Priority to US10/240,413 priority patent/US7829573B2/en
Priority to CZ20023304A priority patent/CZ299410B6/cs
Priority to KR1020087007835A priority patent/KR20080034523A/ko
Priority to CN01807430A priority patent/CN1431902A/zh
Priority to KR1020027013170A priority patent/KR100849149B1/ko
Priority to ES01917305T priority patent/ES2280349T3/es
Priority to EP01917305A priority patent/EP1272186B1/en
Priority to HU0300426A priority patent/HUP0300426A2/hu
Priority to IL15150301A priority patent/IL151503A0/xx
Priority to MXPA02009743A priority patent/MXPA02009743A/es
Priority to NZ520938A priority patent/NZ520938A/en
Priority to CA002401854A priority patent/CA2401854A1/en
Priority to EEP200200578A priority patent/EE200200578A/xx
Priority to SK1430-2002A priority patent/SK14302002A3/sk
Priority to BR0109729-6A priority patent/BR0109729A/pt
Priority to JP2001572104A priority patent/JP2003528917A/ja
Priority to PL01357605A priority patent/PL357605A1/xx
Priority to AU4438601A priority patent/AU4438601A/xx
Priority to AU2001244386A priority patent/AU2001244386B2/en
Priority to PCT/GB2001/001522 priority patent/WO2001074360A1/en
Priority to PT01917305T priority patent/PT1272186E/pt
Priority to DK01917305T priority patent/DK1272186T3/da
Priority to SI200130715T priority patent/SI1272186T1/sl
Priority to EP06003576A priority patent/EP1658849A3/en
Priority to RU2002129353/14A priority patent/RU2002129353A/ru
Priority to AT01917305T priority patent/ATE355065T1/de
Priority to EP07003863A priority patent/EP1790340A3/en
Priority to NZ534455A priority patent/NZ534455A/en
Priority to ZA200206959A priority patent/ZA200206959B/en
Priority to IS6557A priority patent/IS2455B/is
Priority to NO20024814A priority patent/NO323467B1/no
Priority to NO20062050A priority patent/NO326277B1/no
Priority to CY20071100523T priority patent/CY1107615T1/el
Priority to IS8726A priority patent/IS8726A/is
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0008269.3A 2000-04-05 2000-04-05 Combination chemotherapy Ceased GB0008269D0 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
GBGB0008269.3A GB0008269D0 (en) 2000-04-05 2000-04-05 Combination chemotherapy
AU4438601A AU4438601A (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents
BR0109729-6A BR0109729A (pt) 2000-04-05 2001-04-02 Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese
US10/240,413 US7829573B2 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenics agents
CZ20023304A CZ299410B6 (cs) 2000-04-05 2001-04-02 Terapeutické kombinace antihypertenziva a antiangiogenního cinidla
KR1020087007835A KR20080034523A (ko) 2000-04-05 2001-04-02 항고혈압제와 항혈관형성제의 치료 조합물
CN01807430A CN1431902A (zh) 2000-04-05 2001-04-02 抗高血压剂与抗血管生成剂的治疗组合物
KR1020027013170A KR100849149B1 (ko) 2000-04-05 2001-04-02 항고혈압제와 항혈관형성제의 치료 조합물
ES01917305T ES2280349T3 (es) 2000-04-05 2001-04-02 Combinaciones terapeuticas de agentes antihipertensivos y antiangiogenicos.
EP01917305A EP1272186B1 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents
HU0300426A HUP0300426A2 (hu) 2000-04-05 2001-04-02 Antihipertenzív és anti-angiogén szerek terápiás kombinációja és ezeket tartalmazó gyógyszerkészítmények
IL15150301A IL151503A0 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiagiogenic agents
MXPA02009743A MXPA02009743A (es) 2000-04-05 2001-04-02 Combinaciones terapeuticas de agentes antihipertensivos y antiagiogenicos.
NZ520938A NZ520938A (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents
CA002401854A CA2401854A1 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents
EEP200200578A EE200200578A (et) 2000-04-05 2001-04-02 Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid
SK1430-2002A SK14302002A3 (sk) 2000-04-05 2001-04-02 Použitie kombinácie antiangiogénneho a antihypertenzívneho činidla, farmaceutická kompozícia a súprava, ktoré ju obsahujú
DE60126923T DE60126923T2 (de) 2000-04-05 2001-04-02 Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
PL01357605A PL357605A1 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents
JP2001572104A JP2003528917A (ja) 2000-04-05 2001-04-02 抗高血圧薬および抗血管新生薬の治療的組合せ
NZ534455A NZ534455A (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents
AU2001244386A AU2001244386B2 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents
PCT/GB2001/001522 WO2001074360A1 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents
PT01917305T PT1272186E (pt) 2000-04-05 2001-04-02 Combinações terapêuticas de agentes antiangiogénicos e antihipertensores
DK01917305T DK1272186T3 (da) 2000-04-05 2001-04-02 Terapeutiske kombinationer af antihypertensive og antiangiogene midler
SI200130715T SI1272186T1 (sl) 2000-04-05 2001-04-02 Terapevtske kombinacije antihipertenzivnih in antiangiogenskih sredstev
EP06003576A EP1658849A3 (en) 2000-04-05 2001-04-02 therapeutic combinations of antihypertensive and antiangiogenic agents
RU2002129353/14A RU2002129353A (ru) 2000-04-05 2001-04-02 Терапевтические сочетания гипотензивного и антиангиогенного лекарственных средств
AT01917305T ATE355065T1 (de) 2000-04-05 2001-04-02 Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
EP07003863A EP1790340A3 (en) 2000-04-05 2001-04-02 Combination chemotherapy
ZA200206959A ZA200206959B (en) 2000-04-05 2002-08-29 Therapeutic combinations of antihypertensive and antiangiogenic agents.
IS6557A IS2455B (is) 2000-04-05 2002-09-20 Meðferðarsamsetningar úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun
NO20024814A NO323467B1 (no) 2000-04-05 2002-10-04 Farmasoytisk sammensetning som omfatter antihypertensivt middel og en VEGF-reseptortyrosinkinaseinhibitor, et testsett som omfatter middelet og inhibitorene og anvendelse av dem for fremstilling av et medikament
NO20062050A NO326277B1 (no) 2000-04-05 2006-05-08 Anvendelse av terapeutiske kombinasjoner av et vaskulaert malmiddel og et anti-hypertensivt middel for fremstilling av medikament for behandling av sykdom samt et farmasoytisk preparat omfattende disse
CY20071100523T CY1107615T1 (el) 2000-04-05 2007-04-17 Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
IS8726A IS8726A (is) 2000-04-05 2008-04-16 Meðferðarfræðilegar samsetningar þrýstingslækkandi efna og efna sem hamla gegn æðamyndun

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008269.3A GB0008269D0 (en) 2000-04-05 2000-04-05 Combination chemotherapy

Publications (1)

Publication Number Publication Date
GB0008269D0 true GB0008269D0 (en) 2000-05-24

Family

ID=9889176

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0008269.3A Ceased GB0008269D0 (en) 2000-04-05 2000-04-05 Combination chemotherapy

Country Status (29)

Country Link
US (1) US7829573B2 (https=)
EP (3) EP1658849A3 (https=)
JP (1) JP2003528917A (https=)
KR (2) KR100849149B1 (https=)
CN (1) CN1431902A (https=)
AT (1) ATE355065T1 (https=)
AU (2) AU2001244386B2 (https=)
BR (1) BR0109729A (https=)
CA (1) CA2401854A1 (https=)
CY (1) CY1107615T1 (https=)
CZ (1) CZ299410B6 (https=)
DE (1) DE60126923T2 (https=)
DK (1) DK1272186T3 (https=)
EE (1) EE200200578A (https=)
ES (1) ES2280349T3 (https=)
GB (1) GB0008269D0 (https=)
HU (1) HUP0300426A2 (https=)
IL (1) IL151503A0 (https=)
IS (2) IS2455B (https=)
MX (1) MXPA02009743A (https=)
NO (2) NO323467B1 (https=)
NZ (2) NZ520938A (https=)
PL (1) PL357605A1 (https=)
PT (1) PT1272186E (https=)
RU (1) RU2002129353A (https=)
SI (1) SI1272186T1 (https=)
SK (1) SK14302002A3 (https=)
WO (1) WO2001074360A1 (https=)
ZA (1) ZA200206959B (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
SI1474420T1 (sl) * 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
BR0309226A (pt) * 2002-04-16 2005-02-09 Astrazeneca Ab Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
KR101215701B1 (ko) * 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 자간전증 또는 자간의 진단 및 치료 방법
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
JP2006527753A (ja) * 2003-06-18 2006-12-07 アンギオジェン・ファーマシューティカルズ・リミテッド 結腸直腸癌などの治療のための、血管損傷効果を有する、５−ｆｕ、ｃｐｔ−１１または５−ｆｕおよびｃｐｔ−１１と組み合わせたｚｄ６１２６を含んでなる組成物
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0318422D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
AU2004309166B2 (en) * 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
MXPA06010755A (es) * 2004-03-23 2006-12-15 Astrazeneca Ab Terapia de combinacion.
US20070142433A1 (en) * 2004-04-06 2007-06-21 Helmut Augustin Angiogenesis-affecting compounds and methods of use thereof
US20070142308A1 (en) * 2005-04-06 2007-06-21 Helmut Augustin Angiogenesis-affecting compounds and methods for use thereof
EP1737452A1 (en) * 2004-04-06 2007-01-03 Angiogenetics Sweden AB Angiogenesis-affecting compounds and methods of use thereof
US8273383B2 (en) * 2004-05-04 2012-09-25 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
EP2347765B1 (en) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
DE602005023216D1 (de) * 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
MX2007010965A (es) * 2005-03-09 2007-09-19 Merck & Co Inc Antagonistas de canales de calcio de tipo t de quinazolinona.
KR20080031029A (ko) * 2005-07-06 2008-04-07 아스트라제네카 아베 Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
AU2006277742B2 (en) 2005-08-08 2010-08-26 Pfizer Inc. Salts and polymorphs of a VEGF-R inhibitor
CA2615636A1 (en) * 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
HRP20110365T1 (hr) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija azd2171 i pemetrekseda
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
CA2684938A1 (en) * 2007-05-02 2008-11-13 Tau Therapeutics Llc Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
AU2008275674A1 (en) * 2007-07-10 2009-01-15 Merck & Co., Inc. Quinazolinone T-type calcium channel antagonists
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
EP2542155B1 (en) 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN103110614B (zh) * 2013-01-18 2015-02-18 杭州雷索药业有限公司 舒洛地尔在制备抗血管生成类药物中的应用
MX368903B (es) * 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
AU2015243537B2 (en) 2014-04-08 2020-10-22 The Methodist Hospital INOS-inhibitory compositions and their use as breast cancer therapeutics
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
US10265111B2 (en) 2016-04-26 2019-04-23 Medtronic Holding Company Sárl Inflatable bone tamp with flow control and methods of use
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
WO2020028007A1 (en) * 2018-07-31 2020-02-06 Colorado State University Research Foundation Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11484355B2 (en) 2020-03-02 2022-11-01 Medtronic Holding Company Sàrl Inflatable bone tamp and method for use of inflatable bone tamp

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) * 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) * 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
AU2103097A (en) * 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998013350A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
WO1998028006A1 (en) 1996-12-23 1998-07-02 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
ES2289791T3 (es) * 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
ATE405651T1 (de) * 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
US6191144B1 (en) * 1998-08-17 2001-02-20 Warner-Lambert Company Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis
US6352975B1 (en) 1998-09-09 2002-03-05 Scios Inc. Methods of treating hypertension and compositions for use therein
EP1146891B1 (en) * 1999-01-15 2006-12-20 Medstar Research Institute Therapy of restenosis and atherosclerosis with a soluble vegf receptor and angiopoeitin-1
PT1154774E (pt) * 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
US20020068729A1 (en) * 2000-07-13 2002-06-06 Alteon, Inc. Method for treating fibrotic diseases or other indications IC
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR20050100683A (ko) 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
GB0310401D0 (en) 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316127D0 (en) 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
EP1648465B1 (en) 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0316123D0 (en) 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
MXPA06010755A (es) 2004-03-23 2006-12-15 Astrazeneca Ab Terapia de combinacion.
GB0406446D0 (en) 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406445D0 (en) 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
JP2008514576A (ja) 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
KR20070072543A (ko) 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
KR20080031029A (ko) 2005-07-06 2008-04-07 아스트라제네카 아베 Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
HRP20110365T1 (hr) 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija azd2171 i pemetrekseda
PL1971338T3 (pl) 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
WO2008037996A1 (en) 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20100130519A1 (en) 2007-04-13 2010-05-27 Stephen Robert Wedge Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii

Also Published As

Publication number Publication date
DE60126923D1 (de) 2007-04-12
CY1107615T1 (el) 2013-03-13
IL151503A0 (en) 2003-04-10
AU2001244386B2 (en) 2005-01-27
SK14302002A3 (sk) 2003-05-02
ATE355065T1 (de) 2006-03-15
CN1431902A (zh) 2003-07-23
EP1658849A2 (en) 2006-05-24
HUP0300426A2 (hu) 2003-06-28
CZ299410B6 (cs) 2008-07-16
IS2455B (is) 2008-11-15
MXPA02009743A (es) 2003-03-27
EP1790340A3 (en) 2009-03-18
DE60126923T2 (de) 2007-10-31
IS8726A (is) 2008-04-16
NO20062050L (no) 2001-10-08
NZ520938A (en) 2005-08-26
US20030144298A1 (en) 2003-07-31
AU4438601A (en) 2001-10-15
WO2001074360A1 (en) 2001-10-11
BR0109729A (pt) 2003-02-04
PL357605A1 (en) 2004-07-26
EP1272186A1 (en) 2003-01-08
NZ534455A (en) 2007-01-26
US7829573B2 (en) 2010-11-09
RU2002129353A (ru) 2004-03-20
ZA200206959B (en) 2003-12-01
NO20024814D0 (no) 2002-10-04
KR20080034523A (ko) 2008-04-21
EP1790340A2 (en) 2007-05-30
SI1272186T1 (sl) 2007-06-30
KR100849149B1 (ko) 2008-07-31
DK1272186T3 (da) 2007-05-21
IS6557A (is) 2002-09-20
EP1272186B1 (en) 2007-02-28
EE200200578A (et) 2004-06-15
JP2003528917A (ja) 2003-09-30
KR20030007491A (ko) 2003-01-23
NO20024814L (no) 2002-11-12
NO326277B1 (no) 2008-10-27
ES2280349T3 (es) 2007-09-16
NO323467B1 (no) 2007-05-21
CA2401854A1 (en) 2001-10-11
EP1658849A3 (en) 2009-02-18
PT1272186E (pt) 2007-04-30

Similar Documents

Publication Publication Date Title
GB0008269D0 (en) Combination chemotherapy
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
LUC00011I2 (https=)
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
IL188774A0 (en) Compositions for delivery of drug combinations
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
SE0000303D0 (sv) Novel compounds
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
SE0103210D0 (sv) New formulations and use thereof
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
SE0203817D0 (sv) New composition
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
JP2003526659A5 (https=)
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)